Ivabradine for Incessant Atrial Tachycardia in a 1-Year-Old Child After Tetralogy of Fallot Repair

Area of Science:

• Pediatric Cardiology
• Clinical Pharmacology

Background:

• Ivabradine selectively inhibits the If current in the sinoatrial node, reducing heart rate without affecting contractility or blood pressure.
• Limited evidence exists for ivabradine in pediatric arrhythmia management, with most studies focusing on adult heart failure and coronary artery disease.
• Incessant atrial tachycardia is a significant complication following tetralogy of Fallot repair in pediatric patients.

Observation:

• A 1-year-old child developed incessant tachyarrhythmia post-tetralogy of Fallot repair.
• Standard antiarrhythmic therapies including adenosine, amiodarone, beta-blockers, digoxin, and cardioversion were ineffective.
• Ivabradine was administered at 0.1 mg/kg, leading to restoration of sinus rhythm and hemodynamic stability.

Findings:

• Ivabradine administration resulted in successful conversion from incessant atrial tachycardia to sinus rhythm within 8 hours.
• The treatment led to a significant decrease in heart rate and improved hemodynamic status in the pediatric patient.
• The response to ivabradine suggests a potential focal mechanism for the tachycardia, distinct from typical reentry pathways.

Implications:

• Ivabradine presents a promising therapeutic option for managing refractory incessant atrial tachycardia in pediatric patients, particularly after cardiac surgery.
• This case underscores the need for further research into the safety and efficacy of ivabradine for pediatric arrhythmias.
• Understanding the underlying mechanisms of tachycardia in post-TOF repair patients is crucial for guiding targeted therapy.